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Measurement properties of the Dutch
Unite´ Rhumatologique des Affections de la
Main and its ability to measure change due
to Dupuytren’s disease progression
compared with the Michigan Hand
outcomes Questionnaire
Dieuwke C. Broekstra1, Edwin R. van den Heuvel2,
Rosanne Lanting1 and Paul M. N. Werker1
Abstract
Data of a prospective longitudinal cohort study including 233 Dupuytren’s patients was used to determine: (1)
whether the Unite´ Rhumatologique des Affections de la Main scale and Michigan Hand outcomes
Questionnaire can detect change in hand function due to Dupuytren’s disease progression and to compare
their abilities; (2) the concurrent validity, reliability, responsiveness and interpretability of the Dutch Unite´
Rhumatologique des Affections de la Main. The Unite´ Rhumatologique des Affections de la Main and Michigan
Hand outcomes Questionnaire had comparable measurement properties, and were both able to distinguish
participants with disease progression from those without progression (resp. U = 1252.5, p = 0.008, and
U = 1086.0, p< 0.001), but only at a group level. Individual cases of progression could not be detected using
these outcome measures, as indicated by the fact that the smallest detectable change was larger than the
minimal important change, and area under the receiver operating curve (AUC) values of 0.75 for Michigan
Hand outcomes Questionnaire and 0.67 for Unite´ Rhumatologique des Affections de la Main.
Level of evidence: II
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Introduction
There are many patient-reported outcome measures
(PROMs) used for patients with Dupuytren’s disease
(Ball et al., 2013). The Disability of Shoulder, Arm and
Hand (DASH) questionnaire is the one most fre-
quently used, followed by the Michigan Hand
Questionnaire (MHQ) (Ball et al., 2013). These
PROMs are region-specific, evaluating functional
consequences due to hand and arm problems in
general. Thus, whether the DASH and MHQ are
specific enough to be used for patients with
Dupuytren’s disease is unclear. Therefore, a new
disease-specific PROM was developed especially for
use in this patient group, called the Unite´
Rhumatologique des Affections de la Main (URAM)
scale (Beaudreuil et al., 2011). Despite possible
objections, all these PROMs have been tested in
Dupuytren’s populations (Beaudreuil et al., 2011;
Forget et al., 2014; Schoneveld et al., 2009; van de
Ven-Stevens et al., 2015). The DASH was found to be
unsuitable for application in this population since it
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lacked validity, discriminative ability and interpret-
ability (Forget et al., 2014; Rodrigues et al., 2017).
The MHQ, which was tested in a Dutch Dupuytren’s
population that had undergone percutaneous needle
fasciotomy, had adequate construct validity and test–
retest reliability (Schoneveld et al., 2009). The URAM
was found to have adequate internal consistency,
test–retest reliability and responsiveness, but this
was determined by the developers themselves
(Beaudreuil et al., 2011). The applicability of this
PROM has been questioned by Rodrigues et al.
(2015). Their main criticism was that the URAM fails
to assess many activities in which their British popu-
lation of Dupuytren’s patients report functional prob-
lems, such as putting on gloves or problems with
finger hooking, and therefore, the URAM lacks content
validity. Conversely, they used the URAM in a recent
study and concluded that it was responsive to detect
improvement after treatment and that it had accept-
able interpretability (Rodrigues et al., 2017).
Although the MHQ and URAM have been tested in
a Dupuytren’s population undergoing treatment
(Beaudreuil et al., 2011; Schoneveld et al., 2009), it
is not known if these PROMs can detect changes in
hand function due to natural disease progression.
Change due to spontaneous disease progression is
possibly more subtle compared with change after
treatment. Hence, the aim of this study was to deter-
mine whether the URAM and MHQ are able to detect
change due to natural disease progression and to
compare their abilities. A secondary aim of this
study was to determine the concurrent validity, reli-
ability, responsiveness and interpretability of the
Dutch language version of the URAM.
Patients and methods
Participants
Data for 233 adults with Dupuytren’s disease, who
were included in a cohort study on disease course
(Lanting et al., 2016), were used in the current
study. Exclusion criteria were upper extremity prob-
lems that are likely to influence the outcome, and
more missing values than allowed by the question-
naire instructions. All participants gave written
informed consent in accordance with the Helsinki
Declaration. The institutional ethics committee
approved this study.
Outcome measures and instruments
Clinically important disease progression was defined
as change in total passive extension deficit (TPED)
>15 in one finger, since previous research has
shown that the TPED has a maximum measurement
error of 15 per finger (Broekstra et al., 2015). TPED
was measured using a finger goniometer, except for
the thumb. The thumb was not measured, as con-
tractures that are present in the first web space
are not registered in the TPED measure of the
thumb.
The instruments used to measure self-reported
hand function were the URAM (Beaudreuil et al.,
2011) and MHQ (Chung et al., 1999). The URAM
covers one domain (i.e. functional outcome) contain-
ing nine items, which can be awarded 0 to 5 points.
The overall score is calculated by summation of the
nine responses, which can range between 0 and 45
points and where zero points indicate no disability.
The original French URAM was translated to Dutch
(see Appendix S1 available online), according to the
linguistic validation guidelines of mapi (Acquadro
et al., 2012). In case of bilateral disease, the URAM
was filled out for the most severely affected,
untreated hand.
The MHQ is a questionnaire developed to measure
hand function and related outcomes of patients with
various hand conditions. It contains 57 items that
cover six different domains: overall hand function,
activities of daily living (ADL), work-related activities,
pain, aesthetics and satisfaction with hand function.
Except for the domains of work and pain, each
domain is answered for both hands separately.
Each item can be awarded 1 to 5 points. Subscores
per domain are calculated by reversing the scores on
negatively stated items (e.g. How often were you
unable to work?), and then normalized to generate
a score between 0 and 100. Higher overall scores
represent a better outcome. It is also possible to cal-
culate an overall score for each hand separately. In
our analyses, we used the overall score for the most
severely affected untreated hand in instances of
bilateral disease.
Study design and procedures
The measurements took place in the context of a
prospective cohort study with repeated measures
on natural disease course of Dupuytren’s disease
(Lanting et al., 2016). During all measurements
TPED was measured and the Dutch language version
of the MHQ was completed. When the URAM became
available, this PROM was used temporarily parallel to
the MHQ. Later on, the URAM was used instead of the
MHQ (Figure 1). Since for both PROMs two measure-
ments (T1/T1a and T2) were available with an interval
of 6 to 24 months, disease progression could be
determined. For the URAM, there was an extra meas-
urement (T1b) 2 to 4 weeks after the first
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measurement, to determine the test–retest reliabil-
ity. A subsample of 53 participants took part in this
additional measurement. This number is large
enough to obtain an agreement of at least 80% with
a maximum confidence interval (CI) of 0.20 with 0.90
probability assurance (Zou, 2012).
Statistical analyses
Concurrent validity. Concurrent validity indicates
the extent to which the scores of an instrument are
related to the scores of another instrument measur-
ing a similar construct. This was assessed for the
URAM by calculating Spearman’s correlation coeffi-
cient between the scores of the URAM at time point
T1a and MHQ at time moment T2 (see Figure 1).
After Fisher’s z-transformation (Fisher, 1915), 95%
CIs were determined.
Internal consistency, reliability and mea-
surement error. The internal consistency is a
measure that indicates how well the items of the
instrument that measure the same construct are
interrelated. The URAM covers one domain, so the
internal consistency was calculated for all items
using Cronbach’s alpha. The internal consistency
for the MHQ was calculated for each domain separ-
ately. For the pain domain, the internal consistency
was calculated after excluding those who answered
‘Never’ on question 1 (i.e. How often did you have pain
in your hand(s)/wrist(s)?). Cronbach’s alpha was cal-
culated at both measurement time (T1a and T2),
including 95% CIs based on F-tests. A Cronbach’s
alpha between 0.70 and 0.95 was considered good
(Terwee et al., 2007).
As a measure of test–retest reliability, the intra-
class correlation (ICC) for agreement was used. This
indicates whether the questionnaire provides the
same results when it has been filled out twice in
absence of a real change. A one-way random-effects
model, with a random effect for participant
ð2participantÞ and a random error for repeats ð2residualÞ,
was estimated with restricted maximum likelihood.





A 95% CI on de ICCagreement was determined with
the beta-approach (Demetrashvili et al., 2016). An
estimated value of 0.70 or higher was considered
good (Terwee et al., 2007).
The standard error of measurement (SEM) is a
measure to indicate the absolute measurement
error in the scale. It was determined by calculating
Figure 1. Study design.
URAM: Unite´ Rhumatologique des Affection de la Main scale; MHQ: Michigan Hand Questionnaire; PE: physical examination of hands.
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SEM ¼ residual with a 95% CI determined through
Satterthwaite approach (Van den Heuvel, 2010). The
smallest detectable change (SDC) is a measure that
indicates how large a difference in score must be to
be detected by the instrument as a real change. It
was calculated using formula (2):





with a 95% CI borrowed from the interval for SEM. In
addition, the absolute measurement error was visua-
lized using a Bland–Altman plot (Bland and Altman,
1986), providing 95% prediction limits of agreement.
Responsiveness. The responsiveness indicates
how well the instrument is able to detect a change
over time. To determine this, participants who
progressed were separated from those who did not
progress, according to the definition as stated ear-
lier. The URAM and MHQ change scores (T2–T1) of
the two groups were tested for differences using a
Mann–Whitney U test to determine whether the
PROMs were able to detect progression at a group
level. To evaluate their ability to detect progression
at an individual level, the area under the
receiver operating curve (AUC) was determined.
Furthermore, boundary (ceiling or floor) effects
were determined as the percentage of participants
having extension deficits in the fingers, but who
report the best possible score. Large boundary
effects indicate that the instrument is not responsive
in this particular population. Due to the fact that
lower URAM scores represent better outcomes, the
best possible score is the minimal score (floor
effects) for the URAM, while it is a maximal score
(ceiling effects) for the MHQ.
Interpretability. ‘‘Interpretability is the degree to
which one can assign qualitative meaning to an
instrument’s quantitative scores or change in
scores’’ (Mokkink et al., 2010). Therefore, the min-
imal important change (MIC) was calculated, which is
the smallest change score that can be considered as
relevant. It was derived from the reveiver operating
curve (ROC) at the score having the largest sensitivity
and specificity. From the ROC analysis, the corres-
ponding change score was derived.
For all hypothesis tests a significance level of 5%
was applied.
Results
In the first 2 years of the study the MHQ was used,
and 233 participants filled out the MHQ at
T1 (Figure 1). Eleven participants were excluded, so
the analyses on responsiveness and interpretability
of the MHQ were done using data of 222 participants,
because for these analyses a change over time
should be determined. Then the URAM was intro-
duced. So, T2 of the MHQ and T1a of the URAM
occurred simultaneously, and 199 patients filled out
both PROMs at this visit. The URAM data of 208 par-
ticipants was available at T1a. Fifty-three participants
took part in the additional URAM measurement (T1b).
Thereafter, six participants withdrew from participa-
tion, so at T2, 202 participants filled out the URAM.
So, analyses on the responsiveness and interpret-
ability were done using data of 202 participants.
A total of 193 participants filled out both PROMs on
both measurements.
The majority of the participants were male (65%),
and their mean age was 66.1 (SD 10.7). Twenty-one
participants in the URAM dataset had shown clinically
important progression compared with 22 participants
in the MHQ dataset (Table 1).
URAM
Concurrent validity
The URAM and MHQ scores showed a strong correl-
ation (r =0.65 [–0.72; –0.56], p< 0.001). This correl-
ation is negative, since for the URAM a lower score
represents better function, while for the MHQ a
higher score represents better function.
Internal consistency, reliability and
measurement error
The Cronbach’s alpha was calculated for all items
of the URAM and is presented in Table 2 along with
the results for test–retest reliability, the SEM and
SDC. The Bland–Altman upper and lower 95%
limits of agreement were 5.0 and –6.3, respectively
(Figure 2).
Responsiveness
The median change score in the group that showed
clinically important progression was larger than the
change score in the group that showed no clinically
important progression (Table 1). This indicates that
the URAM is able to discriminate between the groups
without and with disease progression. At an individ-
ual level, the URAM has difficulty making this distinc-
tion, as indicated by an AUC of 0.67 [0.53; 0.81]. At T1,
the maximum TPED in 14 participants over 10 fingers
ranged between 4 and 35, although they reported
no functional problems defined by an URAM score of
0 (floor effects, see Table 2). At T2, the maximum
858 Journal of Hand Surgery (Eur) 43(8)























Difference in change score between
those with and without
progression (points)
2.0
(U = 1252.5, p = 0.008)
N = 202
–6.9
(U = 1086.0, p< 0.001)
N = 222





















Table 1. Characteristics of the participants, presented for those who showed clinically important progression and those










N 21 181 22 200
Gender (M/F, % M) 16/5 (76) 116/65 (64) 19/3 (86) 128/72 (64)
Age in years (mean (SD)) 62.5 (8.9) 65.9 (10.4) 68.0 (8.3) 65.6 (10.3)
Time between T1 and T3
in months (median (IQR))
18.0 (17.5–18.0) 18.0 (17.0–18.0) 17.0 (12.0–19.0) 18.0 (12.0–24.0)
Max. TPED at T1 in  (median (IQR)) 0.0 (0.0–10.0) 0.0 (0.0–6.3) 10.0 (5.0–20.0) 0.0 (0.0–21.3)
Max. TPED at T3 in  (median (IQR)) 28.0 (20.0–43.0) 0.0 (0.0–7.0) 42.0 (26.0–68.0) 0.0 (0.0–18.5)
Score at T1 (median (IQR)) 3.0 (1.0–6.0) 0.0 (0.0–4.0) 91.0 (87.0–99.2) 92.5 (78.6–99.7)
Score at T3 (median (IQR)) 6.0 (0.0–8.5) 0.0 (0.0–3.0) 85.9 (73.5–95.8) 90.4 (78.7–98.9)
URAM: Unite´ Rhumatologique des Affections de la Main; MHQ: Michigan Hand Questionnaire; N: number of participants; M/F: male/
female; SD: standard deviation; IQR: interquartile range; TPED: total passive extension deficit.
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TPED in 23 participants ranged between 6 and 66,
while they reported no functional problems in the
URAM (floor effects, see Table 2). None of the
participants reported the worst possible score of
45, neither at T1 nor at T2.
Interpretability
We determined the optimal cut-off point (MIC) for
disease progression, which is presented in Table 2.































Mean difference between T1a and T1b
Mean + 1.96*SD
Mean - 1.96*SD
Figure 2. Bland–Altman plot of the mean URAM score and change score between T1a and T1b. The dashed line
represents the mean difference, and the dotted lines represent the upper and lower prediction limits of agreement.
Table 2. Continued
URAM MHQ






URAM: Unite´ Rhumatologique des Affections de la Main; MHQ: Michigan Hand Questionnaire; ICC: intra-class cor-
relation; SEM: standard error of measurement; AUC: area under the receiver operating curve; MIC: minimal import-
ant change; SDC: smallest detectable change.
aAs the internal consistency for the MHQ was determined for each domain separately, a range is presented here. For
full results, see Table 3.
bThis was not determined in the current study.
cBoundary effects were determined as the number of participants having contractures, among those reporting the
best possible score.
dMIC for MHQ is negative, as a decrease in score indicates a decrease in function.
eSensitivity and specificity when MIC is used as cut-off.
fSensitivity and specificity when SDC is used as cut-off.
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the SDC as cut-off, the sensitivity decreased, but the
specificity increased.
MHQ
Internal consistency, reliability and
measurement error
Since the internal consistency was not determined in
the previous study, we determined the internal con-
sistency by calculating a Cronbach’s alpha for each
domain specified in the MHQ (Table 3). The reliability,
SEM and SDC of the MHQ have already been deter-
mined in Dupuytren’s patients by others (Schoneveld
et al., 2009).
Responsiveness
The change score in the group that showed clinically
important progression was lower than the change
score in the group that showed no clinically import-
ant progression (Table 2). This indicates that the
MHQ can discriminate between those with and with-
out disease progression at a group level. The AUC
was adequate, namely 0.75 [0.66; 0.85] (see
Table 2). At T1, the maximum TPED in 11 participants
over 10 fingers ranged between 5 and 25, although
they reported no functional problems defined by an
MHQ score of 100 (ceiling effects, see Table 2). At T2,
the maximum TPED in two participants was 25 and
52, while they reported no functional problems in
the MHQ (ceiling effects, see Table 2). None of
the participants had the worst possible score of 0,
neither at T1 nor at T2.
Interpretability
The MIC for progression is presented in Table 2. The
SEM and SDC for the MHQ were already determined
by others (Schoneveld et al., 2009). The MIC was
smaller than the SDC. When the SDC was used as
cut-off, the sensitivity decreased, while the specificity
increased.
Discussion
This study shows that the URAM and MHQ are able to
detect Dupuytren’s disease progression at a group
level but not on an individual level. This can be con-
cluded from the results on responsiveness. The AUC
of the URAM was 0.67, and the SDC was larger than
the MIC. The results on responsiveness of the MHQ
are not fully consistent as the AUC was considered
adequate (Terwee et al., 2007), but the MIC that was
found in this study was much smaller than the SDC
reported by Schoneveld et al. (2009). This suggests
that both PROMs cannot detect progression at an
individual level. However, at group level, the change
scores of the group that showed clinically important
progression differed significantly from the group that
did not show clinically important progression, in both
PROMs.
Responsiveness of the URAM is impaired by scale
boundary effects, as 14% (T1a) and 21% (T2) of the
participants who had extension deficit still reported
the minimal score. The MHQ suffered less from
boundary effects (20% (T1) and 5% (T2). The URAM
and MHQ were only used parallel during one moment
in time, which explains the large differences in
boundary effects between the two PROMs.
Furthermore, the smaller scale boundary effects of
the MHQ might be a logical consequence of the
length of this questionnaire (57 vs. 9 items in
URAM). So, with the MHQ it is less likely to get the
maximal score. However, the length of the MHQ can
also be considered as a drawback. Many participants
complained about the length of this questionnaire
and the difficulty of some double-negative items.
Some refused to fill out the MHQ repeatedly, while
others were not able to fill it out independently.
A brief version of the MHQ is also available (in
English) (Waljee et al., 2011) and might solve this prob-
lem. It will be interesting to evaluate its ability to detect
disease progression compared with the URAM.
Table 3. Internal consistency (Cronbach’s alpha) pre-
sented for each domain of the MHQ, separately for the left
and right hand at T1 and T2.
Domain
Cronbach’s alpha [95% CI]
T1 T2
Overall hand function
Right hand 0.93 [0.91; 0.94] 0.93 [0.92; 0.94]
Left hand 0.94 [0.93; 0.95] 0.94 [0.93; 0.95]
Activities of daily living
Right hand 0.88 [0.85; 0.90] 0.91 [0.88; 0.92]
Left hand 0.90 [0.88; 0.92] 0.91 [0.88; 0.92]
Both handsa 0.85 [0.82; 0.88] 0.85 [0.81; 0.88]
Work performance 0.94 [0.93; 0.95] 0.95 [0.93; 0.96]
Pain 0.74 [0.63; 0.81] 0.78 [0.69; 0.83]
Aesthetics
Right hand 0.73 [0.66; 0.78] 0.76 [0.70; 0.81]
Left hand 0.68 [0.61; 0.74] 0.74 [0.68; 0.79]
Satisfaction with hand function
Right hand 0.90 [0.88; 0.92] 0.91 [0.88; 0.92]
Left hand 0.93 [0.91; 0.94] 0.92 [0.90; 0.93]
aThis is a separate part of the questionnaire, in addition to the ADL
part for the right and left hand. ADL: activities of daily living.
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Additionally, reverse-worded items in the MHQ were
frequently filled out incorrectly (e.g. if a participant
responds to have no functional restraints in the posi-
tive items and responds to have maximal restraints in
the negative items).
We further demonstrated that the internal consist-
ency of the URAM was good, and it was higher in the
current study than reported by the developers
(Beaudreuil et al., 2011). This might be caused by
the difference in populations, as the majority of the
participants in our study did not have any functional
complaints, as indicated by a median score of zero. In
the study of Beaudreuil et al. (2011) the included par-
ticipants were patients undergoing treatment, and
higher URAM scores were reported.
The test–retest reliability of the URAM was 0.76
[0.64; 0.87], which is lower than previously reported
values of 0.97 [0.94; 0.98] (Beaudreuil et al., 2011) but
still considered good (Terwee et al., 2007). The test–
retest reliability of the MHQ was not determined in
the current study, but Schoneveld et al. determined
that it is 0.89 (Schoneveld et al., 2009).
This study has some limitations. First of all, we
used the maximal TPED as the cut-off variable to
determine progression. We chose this instead of
the sum of TPEDs in one hand, because we assumed
that one finger with a large TPED will result in
equally large functional restraints compared with
two or more fingers with a large TPED. The two vari-
ables were highly correlated (r = 0.96, p< 0.001), so it
is likely that the results would be similar when the
sum of TPEDs was used as the cut-off. We repeated
the analyses using the sum of TPEDs as the cut-off,
and similar results were found.
Second, by choosing change in maximal TPED of
15 as the cut-off value for the definition of progres-
sion, participants with a change in TPED 15 in all
fingers would end up in the same group as the par-
ticipants without any contractures at both measure-
ments. It is likely that the participants with
contractures would report different PROM scores
than those without.
Third, it is known that TPED measurements are
only weakly correlated to the PROM scores that
patients report (Budd et al., 2011; Degreef et al.,
2009; Jerosch-Herold et al., 2011). However, the
reference variable to discriminate those with and
without progression remains an arbitrary choice,
with each having advantages and limitations. As
TPED has a known measurement error, derived
from the same population, we chose for TPED to
determine progression.
Lastly, the time between T1 and T2 was short
(15–25 months). It is likely that the number of
patients who showed clinically important progression
will become larger when the time between T1 and T2
is longer. However, the median number of months
between T1 and T2 was equal for those with clinically
important progression compared with those without
clinically important progression, and it was even
smaller for those with progression (MHQ). So, it
seems that the time between T1 and T2 was long
enough for disease progression to occur.
The results of this study show that both the URAM
and MHQ have comparable measurement properties.
Based on this, both PROMs can be used in a
Dupuytren’s population, although the length (and
consequently, the low acceptance) of the MHQ
makes it less suitable for longitudinal studies. We
further demonstrated that both PROMs are suitable
to measure change in hand function due to natural
disease progression in patients with Dupuytren’s dis-
ease, but only at a group level. This means that these
PROMs cannot be used to detect progression in a
single person.
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